London · Delayed Price · Currency is GBP · Price in GBX AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of GBP 186.22 billion. The enterprise value is 206.91 billion.
| Market Cap | 186.22B |
| Enterprise Value | 206.91B |
Important Dates
The next confirmed earnings date is Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Aug 6, 2026 |
Share Statistics
AstraZeneca has 1.55 billion shares outstanding. The number of shares has decreased by -0.03% in one year.
| Current Share Class | 1.55B |
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 74.06% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 23.85 and the forward PE ratio is 14.97. AstraZeneca's PEG ratio is 1.21.
| PE Ratio | 23.85 |
| Forward PE | 14.97 |
| PS Ratio | 4.03 |
| PB Ratio | 4.91 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 23.16 |
| P/OCF Ratio | 18.03 |
| PEG Ratio | 1.21 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.53, with an EV/FCF ratio of 25.73.
| EV / Earnings | 26.28 |
| EV / Sales | 4.47 |
| EV / EBITDA | 13.53 |
| EV / EBIT | 18.77 |
| EV / FCF | 25.73 |
Financial Position
The company has a current ratio of 0.89, with a Debt / Equity ratio of 0.64.
| Current Ratio | 0.89 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.64 |
| Debt / EBITDA | 1.59 |
| Debt / FCF | 3.03 |
| Interest Coverage | 10.40 |
Financial Efficiency
Return on equity (ROE) is 21.96% and return on invested capital (ROIC) is 16.05%.
| Return on Equity (ROE) | 21.96% |
| Return on Assets (ROA) | 8.02% |
| Return on Invested Capital (ROIC) | 16.05% |
| Return on Capital Employed (ROCE) | 17.37% |
| Weighted Average Cost of Capital (WACC) | 5.17% |
| Revenue Per Employee | 481,286 |
| Profits Per Employee | 81,927 |
| Employee Count | 96,100 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.68 |
Taxes
In the past 12 months, AstraZeneca has paid 1.61 billion in taxes.
| Income Tax | 1.61B |
| Effective Tax Rate | 16.95% |
Stock Price Statistics
The stock price has decreased by -1.67% in the last 52 weeks. The beta is 0.20, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -1.67% |
| 50-Day Moving Average | 12,618.56 |
| 200-Day Moving Average | 13,711.62 |
| Relative Strength Index (RSI) | 46.02 |
| Average Volume (20 Days) | 3,313,506 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of GBP 46.25 billion and earned 7.87 billion in profits. Earnings per share was 5.03.
| Revenue | 46.25B |
| Gross Profit | 37.78B |
| Operating Income | 11.03B |
| Pretax Income | 9.49B |
| Net Income | 7.87B |
| EBITDA | 15.00B |
| EBIT | 11.03B |
| Earnings Per Share (EPS) | 5.03 |
Balance Sheet
The company has 3.74 billion in cash and 24.38 billion in debt, with a net cash position of -20.64 billion or -13.31 per share.
| Cash & Cash Equivalents | 3.74B |
| Total Debt | 24.38B |
| Net Cash | -20.64B |
| Net Cash Per Share | -13.31 |
| Equity (Book Value) | 37.96B |
| Book Value Per Share | 24.44 |
| Working Capital | -2.70B |
Cash Flow
In the last 12 months, operating cash flow was 10.33 billion and capital expenditures -2.29 billion, giving a free cash flow of 8.04 billion.
| Operating Cash Flow | 10.33B |
| Capital Expenditures | -2.29B |
| Depreciation & Amortization | 3.90B |
| Net Borrowing | -1.40B |
| Free Cash Flow | 8.04B |
| FCF Per Share | 5.18 |
Margins
Gross margin is 81.69%, with operating and profit margins of 23.86% and 17.02%.
| Gross Margin | 81.69% |
| Operating Margin | 23.86% |
| Pretax Margin | 20.51% |
| Profit Margin | 17.02% |
| EBITDA Margin | 32.43% |
| EBIT Margin | 23.86% |
| FCF Margin | 17.71% |
Dividends & Yields
This stock pays an annual dividend of 2.39, which amounts to a dividend yield of 2.00%.
| Dividend Per Share | 2.39 |
| Dividend Yield | 2.00% |
| Dividend Growth (YoY) | -2.33% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 45.73% |
| Buyback Yield | 0.03% |
| Shareholder Yield | 2.03% |
| Earnings Yield | 4.23% |
| FCF Yield | 4.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for AstraZeneca is 15,695.74, which is 30.73% higher than the current price. The consensus rating is "Buy".
| Price Target | 15,695.74 |
| Price Target Difference | 30.73% |
| Analyst Consensus | Buy |
| Analyst Count | 24 |
| Revenue Growth Forecast (3Y) | 6.67% |
| EPS Growth Forecast (3Y) | 11.44% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.57 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.57 |
| Piotroski F-Score | 7 |